Dr. Reddy's Laboratories' stock price has increased to Rs. 6914.00, gaining 19.70 points or 0.29% from its previous close of Rs. 6894.30 on the BSE.

The stock opened at Rs. 6885.00, hitting a high of Rs. 6950.00 and a low of Rs. 6868.70 during the trading session. A total of 4107 shares have been traded so far.

This BSE group 'A' stock, with a face value of Rs. 5, reached a 52-week high of Rs. 7030.00 on July 29, 2024, and a 52-week low of Rs. 5212.10 on October 30, 2023.

Over the past week, the stock's high and low were Rs. 7030.00 and Rs. 6736.60 respectively. The company's current market capitalization stands at Rs. 115273.48 crore.

The company's shareholding pattern shows that promoters hold 26.65%, while institutions and non-institutions hold 48.40% and 10.36% respectively.

Aurigene Oncology (AOL), a wholly-owned subsidiary of Dr. Reddy's Laboratories, has invested Rs. 2.08 crore in Clean Renewable Energy KK 2A (CREL). CREL allotted 20,21,600 equity shares of Rs. 10 each at a premium of Rs. 0.32 per share to AOL on July 31, 2024. The funds provided by AOL will be used to cover the development costs of the project in line with Group Captive norms.

Dr. Reddy's Laboratories, headquartered in Hyderabad, Telangana, India, is a multinational pharmaceutical company that produces and markets a wide variety of pharmaceuticals both in India and internationally.